CXCL9 and neoplasm: In line with the notion of an intrinsically already-inflamed tumour microenvironment of BRCA-mutated tumours, Cxcl9 overexpression in Brca2−/− cells did not significantly improve the onset of ascites (median 36 vs. 32 days; P = 0.14) or overall survival (median 48 vs. 44 days; P = 0.22; Fig. 3i) to the degree as was seen in the BrcaWT model.